You are about to leave a GSK website

Third party content disclaimers

 

You are about to leave a GSK website. By clicking this link, you will be taken to a website that is independently operated and not managed by GSK. The website you are linking to is not controlled or endorsed by GSK and GSK assumes no responsibility for the content on the website. If you wish to proceed, click "OK". If you do not wish to leave this website, click “CANCEL”.

OK

CANCEL

Clobevate-logo

Product menu

  • Reliable First Line Choice for SRDs
    Reliable First-Line Choice for SRDs*1
    Indicated across major inflammatory conditions — Psoriasis, DLE, LSC, and Contact Dermatitis.*1
    LEARN MORE
  • Clobetasol begins calming inflamation within hours
    When Quick Relief Matters: Visible Improvement by Week 12,3
    Clobetasol begins calming inflammation within hours, with measurable results by Day 7.2,3
  • Clobevate leads a legacy of trust in expert recommendations
    No. 1 Prescribed Clobetasol Brand in Pakistan4
    Clobevate leads a legacy of trust in expert recommendations.5

Prevalence

Prevalence Prevalence

Clobevate: The Clobetasol Clinicians Rely On1,2,3

Clobevate (Clobetasol Propionate 0.05%) is a very potent topical corticosteroid indicated for the treatment of steroid-responsive dermatoses (SRDs).1
It offers rapid reduction in inflammation, erythema, and pruritus across a spectrum of chronic and relapsing skin conditions.6,7,17

  1. Visible improvement within a week
  2. Suitable for adults and children over 1 year of age
  3. Available in both ointment and cream formulations
Clobevate-packshots Clobevate-packshots

Designed for difficult-to-treat inflammatory dermatoses

Designed for difficult-to-treat inflammatory dermatoses1

Clobevate (Clobetasol Propionate 0.05%) is indicated for a range of steroid-responsive dermatoses (SRDs) in adults and children over 1 year of age.

Psoriasis

Psoriasis1,2,3

Affects 2–3% of people globally. 
Characterised by red, thickened patches with silvery scales. A go-to psoriasis treatment in Pakistan.

Active discoid lupus

Discoid Lupus Erythematosus (DLE)1,6

Chronic form of cutaneous lupus with scaly, coin-shaped lesions. Clobevate helps manage inflammation and prevents scarring.

Contact Dermatitis

Contact Dermatitis1,7,9

Affects up to 20% of the population. Clobevate quickly relieves itching and irritation caused by contact with allergens or irritants.

lichen simplex chronicus

Lichen Simplex 
Chronicus1,13

Repetitive scratching leads to thickened, itchy skin. Clobevate breaks the itch-scratch cycle and promotes healing.

Why Choose Clobevate?1-4

Time Icon

Fast, Visible Relief: Begins working within hours with noticeable results by Day 7.

Longer remission

Longer Remission: Fewer relapses and better long-term symptom control.

Proven Efficacy

Proven Efficacy: Outperformed other topical steroids like betamethasone dipropionate in clinical studies.

Rank Icon

The No. 1 prescribed clobetasol brand in Pakistan, with over 100 units sold per minute.

Proven Efficacy with Clobevate
Proven Efficacy with Clobevate

Clinical Comparison vs. Betamethasone Dipropionate (BDP)

  1. Greater reduction in lesion severity at 2 weeks2
  2. Significantly longer remission duration post-treatment (p<0.001)14

Quick and Proven Relief in Psoriasis(excluding widespread plaque psoriasis)2,14

Clobetasol Propionate provided significantly greater improvement in moderate to severe psoriasis compared to BDP ointment after just 2 weeks of treatment. Follow-up evaluations showed longer remissions with Clobetasol Propionate (p < 0.001), confirming its sustained clinical benefit.

75% Reduction in Lesion Severity with Clobetasol-treated patients2,14

In patients with psoriasis, Clobevate (Clobetasol Propionate) achieved a 22% reduction in lesion severity after 2 weeks, compared to just 2% with BDP ointment. Nearly 48% of patients showed visible improvement on both treatment sites, with clobetasol-treated areas demonstrating significantly better outcomes. Lower Exacerbation Rates with Clobevate

Reduced Post-Treatment Exacerbations2,14

Only 8% of clobetasol-treated sites experienced exacerbations, compared to 45% of BDP-treated sites, in patients with psoriasis. 
Clobevate provided longer-lasting control and fewer relapses post-treatment, even in patients with bilateral lesions.

Superior Safety and Efficacy vs. Fluocinonide15

Clobetasol was more effective than fluocinonide in all psoriasis categories (p < 0.05), with fewer relapses and faster healing after the first week. Side effects occurred in only 4% of patients using clobetasol, compared to 12% with fluocinonide, underscoring its safety advantage.

  Discover Efficacy Studies

Dosage Guideline1,16,17

1. OINTMENT1

Ideal for: Dry, thickened, or lichenified (hardened and leathery) skin lesions.
Texture & Use: The ointment base is oilier and more occlusive, making it especially effective for retaining moisture in dry, scaly areas.
Best suited for:

  • Chronic skin conditions with thickened plaques
  • Areas where moisture retention is needed
  • Night-time application for enhanced absorption
Clobevate Oinment
Clobevate Oinment

2. CREAM1

Ideal for: Moist, weeping, or inflamed skin lesions.
Texture & Use: The cream formulation is lighter and more cosmetically acceptable, absorbing quickly into the skin.
Best suited for:

  • Weeping lesions (e.g., eczema with fluid discharge)
  • Flexural areas (like underarms or behind knees)
  • Genital areas, where the skin is more sensitive and prone to irritation
Clobevate Cream
Clobevate Cream

Not all steroid creams are created equal. The original clobetasol formulation in Clobevate includes propylene glycol for better skin absorption and clinical consistency.1

Dosage Recommendation By Age Group1,16,17

Clobevate Graph Clobevate Graph

Prescription Reminders:1

Detailed information on Clobavate ointment and cream, including potency, dosage, duration, application, and warnings. Detailed information on Clobavate ointment and cream, including potency, dosage, duration, application, and warnings.

Clear Guidance for Confident Decision-Making

Clear Guidance for Confident Decision-Making

Guidelines

Guidelines & Efficacy

Learn about the usage guidelines and the proven effectiveness of Clobevate in treating the skin

Read More

Dosage and Administration

Dosage & Administration

Get detailed guidance on dosage, formulations, contraindications and safety precautions for Clobevate

Read More

Indication

Indications

Discover conditions Clobevate treats and learn how it can help manage patient's skin

Read More

Safety Information1

Contraindications 
The following conditions should not be treated with CLOBEVATE
1. Untreated cutaneous infections
2. Rosacea
3. Acne vulgaris 
4. Pruritus without inflammation 
5. Perianal and genital pruritus 
6. Perioral dermatitis 

CLOBEVATE is contraindicated in dermatoses in children under one year of age, including dermatitis. 

Common adverse reactions: pruritus, local skin burning /skin pain.

References 
 

  1. Clobevate (Clobetasol Propionate) prescribing information, Version Number: GDS15 IPI08 Date of Issue: 15 July 2020.
  2. Psoriasis.org;2022;1-4;About Psoriasis
  3. Damiani G;Frontiers in Medicine;2021;8;1-11
  4. IQVIA MAT S1-2024
  5. Globalpsoriasisatlas;2024;1-2;prevalence data of psoriasis in Pakistan.
  6. DermNetNZ;2022;1-4;Discoid Lupus Erythematosus
  7. Usatine RP;American family physician;2010;82;249-55, (KC)
  8. Prado de Oliveira;Pediatric Dermatology;2008;1-6
  9. Mayo Clinic;2024;1-12;Contact dermatitis
  10. Adler BL, DeLeo VA. Allergic Contact Dermatitis. JAMA Dermatol. 2021;157(3):364. doi:10.1001/jamadermatol.2020.5639
  11. Sarfraz Z;Annals of Medicine and Surgery;2022;74;1-7
  12. Astindari S;Journal of Pakistan Association of Dermatologists.2023;33;220-234
  13. Lichen Simplex Chronicus - StatPearls - NCBI Bookshelf (nih.gov)-2023;1-5
  14. Jacobson C, Cornell RC, Savin RC. A comparison of clobetasol propionate 0.05 percent ointment and an optimized betamethasone dipropionate 0.05 percent ointment in the treatment of psoriasis. Cutis. 1986;37(3):213-220.
  15. Jegasothy B, et al. Clobetasol vs fluocinonide in psoriasis/eczema. Int J Dermatol. 1985;24(7):461-465.
  16. Harding SM, et al. Neurodermatitis management. Clin Exp Dermatol. 1985;10:13-21.
  17. Hougier FG, et al. Aesthetic corticosteroid use. J Clin Aesthet Dermatol. 2015;8(Suppl 1):S2-S14.

GlaxoSmithKline Pakistan Limited
35-Dockyard Road, West Wharf, Karachi - 74000.
Trademarks are owned by or licensed to the GSK Group of Companies.
GlaxoSmithKline Pakistan Limited is a member of GlaxoSmithKline Group of Companies.
© 2025 GSK group of companies or its licensor.

Adverse Events must be reported. For products related to GSK Pakistan, please report adverse events via email at pk_pharmasafety@gsk.com or call us at +92 (21) 111 475 725 - Ext: 7&8.
Online: Patient Safety Reporting Forum

PM-PK-COP-WCNT-250006 l Date of Preparation: June 2025